Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Post by Moneymagnet14on Mar 04, 2015 7:12am
67 Views
Post# 23487321

Amazing News!!

Amazing News!!Read where Dr.Mohammeds last job posting was with. VANCOUVER, British Columbia, March 4, 2015 /PRNewswire/ -- InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company specializing in the development of cannabinoid based therapies, today announced that it has appointed former Associate Medical Director of GW Pharmaceuticals, Abo Mohammed, MD, DPM, MFPM, as Chief Medical Officer, effective immediately. Dr. Mohammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. As Chief Medical Officer, Dr. Mohammed will join InMed's executive management team and will be directly involved in developing the clinical trial strategy for InMed's lead candidates and product development strategy for the Company's pipeline of cannabinoid based therapies, including its two clinical stage programs, CTI-085 and CTI-091, and the recently initiated program for Epidermolysis bullosa simplex (EBS), INM-750. https://www.prnewswire.com/news-releases/inmed-pharmaceuticals-appoints-dr-abo-mohammed-as-chief-medical-officer-300045164.html
Bullboard Posts